Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul A Reilly

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Polish Archives of Internal Medicine|February 2, 2017
Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysmAnna Tomaszuk-Kazberuk, Paulina Łopatowska, Elżbieta Młodawska, et al.
Journal of the American College of Cardiology|May 13, 2014
Reply: regarding the effect of dabigatran plasma concentrationsPaul A Reilly, Stuart J Connolly, Salim Yusuf, et al.
British Journal of Clinical Pharmacology|February 22, 2012
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicinSebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, et al.
Journal of Clinical Pharmacology|September 30, 2011
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulationThorsten Lehr, Sebastian Haertter, Karl-Heinz Liesenfeld, et al.
British Journal of Clinical Pharmacology|January 11, 2013
Response to the letter by Dr Chin and co-workersSebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 30, 2012
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trialPeter Bytzer, Stuart J Connolly, Sean Yang, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolismManuela Albisetti, Arno Schlosser, Martina Brueckmann, et al.
European Journal of Heart Failure|July 12, 2013
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trialJorge Ferreira, Michael D Ezekowitz, Stuart J Connolly, et al.
Stroke|April 12, 2012
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trialRobert G Hart, Hans-Christoph Diener, Sean Yang, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized studyMasahiro Yasaka, Ippei Ikushima, Akiko Harada, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Polish Archives of Internal Medicine|February 2, 2017
Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysmAnna Tomaszuk-Kazberuk, Paulina Łopatowska, Elżbieta Młodawska, et al.
Journal of the American College of Cardiology|May 13, 2014
Reply: regarding the effect of dabigatran plasma concentrationsPaul A Reilly, Stuart J Connolly, Salim Yusuf, et al.
British Journal of Clinical Pharmacology|February 22, 2012
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicinSebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, et al.
Journal of Clinical Pharmacology|September 30, 2011
Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulationThorsten Lehr, Sebastian Haertter, Karl-Heinz Liesenfeld, et al.
British Journal of Clinical Pharmacology|January 11, 2013
Response to the letter by Dr Chin and co-workersSebastian Härtter, Michael Koenen-Bergmann, Ashish Sharma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 30, 2012
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trialPeter Bytzer, Stuart J Connolly, Sean Yang, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolismManuela Albisetti, Arno Schlosser, Martina Brueckmann, et al.
European Journal of Heart Failure|July 12, 2013
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trialJorge Ferreira, Michael D Ezekowitz, Stuart J Connolly, et al.
Stroke|April 12, 2012
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trialRobert G Hart, Hans-Christoph Diener, Sean Yang, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized studyMasahiro Yasaka, Ippei Ikushima, Akiko Harada, et al.
Pageof 6